Concentrated Insulins: Clinical Update of Therapeutic Options
The DOI matches its Crossref record; 66 of the 68 references it cites were found in a registry or an index.
Abstract
Improved glycemic control is associated with a reduced risk of diabetic complications. Optimal management of patients with type 2 diabetes includes nutritional therapy, physical activity and pharmacotherapy for glycemic control. Most patients with type 2 diabetes are initially managed with oral antidiabetic agents, but as β-cell function declines and the disease progresses, insulin therapy is frequently needed to maintain glycemic control. Insulin therapy given with multi-dose insulin injection regimen or by continuous insulin infusion is needed for patients with type 1 diabetes to achieve control. Obesity and its associated insulin resistance contribute to greater insulin requirements in patients with both type 1 and type 2 diabetes to achieve glycemic control, creating a need for concentrated insulin. Concentrated insulin formulations can be prescribed as an alternative to U100 insulin and provide the advantage of low injection volume, leading to less pain and possibly fewer insulin injections. This review includes a stepwise analysis of all currently available concentrated insulin products, analyzes the most up-to-date evidence, and presents this in combination with expert guidance and commentary in an effort to provide clinicians with a thorough overview of the characteristics and benefits of concentrated insulins in patients with type 1 and type 2 diabetes-instilling confidence when recommending, prescribing, and adjusting these medications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Long-acting GLP-1 RAs also reduce fasting glucose.1099”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1099]
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., Thaler, L. M., & Kitabchi, A. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8341 · Cited by 2,195
Self-citationOgden, C. L., Carroll, M. D., Lawman, H. G., Fryar, C. D., Kruszon-Moran, D., Kit, B. K., & Flegal, K. M. (2016) · JAMA · doi:10.1001/jama.2016.6361 · Cited by 2,178
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444
Self-citation
Cited by
Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study
Wang, L., Yu, W., Yin, X., Cui, L., Tang, S., Jiang, N., Cui, L., Zhao, N., Lin, Q., Chen, L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.21106 · Cited by 573
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationDeardorff, W. J., Cenzer, I. S., Nguyen, B., & Lee, S. J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.6745 · Cited by 146
Risk of Subsequent Fractures in Postmenopausal Women After Nontraumatic vs Traumatic Fractures
Crandall, C. J., Larson, J. C., LaCroix, A. Z., Robbins, J. A., Wactawski‐Wende, J., Johnson, K., Sattari, M., Stone, K. L., Weitlauf, J. C., Gure, T. R., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2617 · Cited by 73
Schacter, G. I., & Leslie, W. D. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.005 · Cited by 62
Sing, C., Lin, T., Bartholomew, S., Bell, J. S., Bennett, C., Beyene, K. A., Bosco‐Lévy, P., Chan, A. H. Y., Chandran, M., Cheung, C., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047258 · Cited by 57
Romosozumab: A Review in Postmenopausal Osteoporosis
Paik, J., & Scott, L. J. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00793-8 · Cited by 56
Yong, E., Cheong, W. F., Huang, Z., Thu, W. P. P., Cazenave‐Gassiot, A., Seng, K. Y., & Logan, S. J. S. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153680 · Cited by 51
The Relationship Between Osteoporosis and Intestinal Microbes in the Henan Province of China
Qin, Q., Yan, S., Yang, Y., Chen, J., Yan, H., Li, T., Gao, X., Wang, Y., Li, A., Wang, S., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.752990 · Cited by 49
Role of bone-forming agents in the management of osteoporosis
McClung, M. R. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01708-8 · Cited by 46
Subclinical Hyperthyroidism: A Review of the Clinical Literature
Tsai, K., & Leung, A. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.02.002 · Cited by 45
Nonrespiratory Comorbidities in Asthma
Cardet, J. C., Bulkhi, A. A., & Lockey, R. F. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.08.027 · Cited by 44
Mehta, R., Goldenberg, R., Katselnik, D., & Kuritzky, L. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1925148 · Cited by 29
Racial disparities, FRAX, and the care of patients with osteoporosis
Lewiecki, E. M., Wright, N. C., & Singer, A. J. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05655-y · Cited by 26
After the initial fracture in postmenopausal women, where do subsequent fractures occur?
Crandall, C. J., Hunt, R., LaCroix, A. Z., Robbins, J. A., Wactawski‐Wende, J., Johnson, K., Sattari, M., Stone, K. L., Weitlauf, J. C., Gure, T. R., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100826 · Cited by 22
Update on Rare Adverse Events from Osteoporosis Therapy and Bisphosphonate Drug Holidays
Adler, R. A. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.003 · Cited by 21
Kocjan, T., Rajic, A. S., Janež, A., Vidmar, G., Orehek, N., Marc, J., & Ostanek, B. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.05.012 · Cited by 19
Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men
Pezzaioli, L. C., Porcelli, T., Delbarba, A., Maffezzoni, F., Focà, E., Castelli, F., Cappelli, C., Ferlin, A., & Quirós-Roldán, E. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01665-7 · Cited by 18
Operationalizing Treat-to-Target for Osteoporosis
Lewiecki, E. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.970 · Cited by 17
Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis
Zeytinoglu, M., Naaman, S., & Dickens, L. T. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.004 · Cited by 17
Chandran, M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.019 · Cited by 15
Frisoli, A., Paes, Â. T., Kimura, A. R. D., de Azevedo, E., & Ambrosio, V. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101134 · Cited by 12
Kline, G. A., Morin, S. N., Feldman, S., Lix, L. M., & Leslie, W. D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab211 · Cited by 12
Albert, S. G., & Wood, E. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.06.015 · Cited by 12
Zhu, S., Li, Y., Wang, L., Huang, J., Song, K., Gan, X., Xiang, X.-N., He, C., & Yang, L. (2022) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2022.3149483 · Cited by 11
Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic
Alfadhli, E. M. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.02.003 · Cited by 10
Yu, W., Zhang, Z., Pan, W. R., Guan, W., Lin, Q., Xia, W., Li, T., & Hsieh, E. (2021) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2021.01.003 · Cited by 9
An, N., Lin, J., & Fei, Q. (2021) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-021-04476-2 · Cited by 8
Huang, C., Cheng, C.-J., Chiou, W.-F., Chang, W., Kang, Y., & Lee, M. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114732 · Cited by 9
Kim, B. K., Kim, C. H., & Min, Y. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1193 · Cited by 7
Ferreira‐Hermosillo, A., & Elías-López, D. (2026) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m21000013 · Cited by 7
Radiographic Diagnosis of Systemic Diseases Manifested in Jaws
Ko, E. M., Omolehinwa, T. T., Akintoye, S. O., & Mupparapu, M. (2021) · Dental Clinics of North America · doi:10.1016/j.cden.2021.02.006 · Cited by 6
Chu, P. Y., Parimi, N., Wolf, R. M., Brown, E. A., Kelly, A. T., & Marks, B. E. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251359167 · Cited by 5
“11,12 However, the safety and effectiveness of U200-AID remain largely unexplored, and U200 is not currently approved for use in AID.”
Insulin’s Legacy: A Century of Breakthroughs and Innovation
Hadid, S. A., Zhang, E., Frishman, W. H., & Brutsaert, E. F. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000680 · Cited by 4
The Nuances Surrounding Insulin Prescribing
McKee, A. M., Yancey, A. M., Zhang, R. M., & McGill, J. B. (2023) · Clinical Diabetes · doi:10.2337/cd22-0117 · Cited by 3
Self-citationOlsen, M. T., Spanakis, E. K., Thabit, H., Dhatariya, K., Mustafa, O. G., Avari, P., Lumb, A. N., Dungan, K. M., Philis‐Tsimikas, A., Kulasa, K. M., et al. (2026) · Diabetes Care · doi:10.2337/dci26-0091 · Cited by 3
Self-citationEfficacy and safety of calcium and vitamin D supplementation to prevent osteoporotic fracture
Kim, B. T. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.4.305 · Cited by 2
Practical considerations for using concentrated U200 insulin in automated insulin delivery systems
Marks, B. E., Chu, P. Y., Parimi, N., Wolf, R. M., Tran, M., & Berget, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1692589 · Cited by 1
“Whereas U500 human insulin has an action time of 18.1-21.5 hours, the action time for U100 is 4 – 6 hours (24, 25) which limits its use in AID.”
InfluentialOlsen, M. T., Spanakis, E. K., Thabit, H., Dhatariya, K., Mustafa, O. G., Avari, P., Lumb, A. N., Dungan, K. M., Philis‐Tsimikas, A., Kulasa, K. M., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06838-8 · Cited by 1
“Pending further evidence, the expert panel recommends prioritising CGM, non-AID insulin pump or AID for non-critically ill hospitalised individuals at high risk of hypogly-caemia [42–45] or hyperglycaemia [42, 46–49] with final decisions guided by individual clinical judgement (Table 1).”
Self-citationEvidence-based treatment of osteoporotic vertebral compression fracture
Lee, S., Cho, D.-C., Kim, K., & Lee, Y. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.3.200 · Cited by 1
Bisphosphonate: An Invaluable Medication or Abandoned Acid?
Chung, H., Lee, J. W., Um, J., & Sohn, H.-S. (2021) · Journal of the Korean Fracture Society · doi:10.12671/jkfs.2021.34.3.122 · Cited by 1
Osteoporosis in premenopausal women, pregnancy, and lactation
Nair, N., Liu, M., & Cohen, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00038-1 · Cited by 1
Who should be screened for osteoporosis?
Crandall, C. J., & Ensrud, K. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00062-9
Denosumab (RANKL Inhibitor): A Potent Anti-Resorptive Agent
Byun, S. (2021) · Journal of the Korean Fracture Society · doi:10.12671/jkfs.2021.34.4.142
Technologies for Diabetes, volume III
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-7888-9
Drummond, R. F., Seif, K. E., & Reece, E. A. (2026) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2026.07.009
Švehlíková, E., Gatschelhofer, C., Lackner, B., Ratzer, M., Fluhr, G., Stoisser, A., Kolaric, G., GERRING, D. J., Howell, S. J., Ježek, J., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71150
“mL), concentrated insulins offer significant clinical advantages by reducing injection volume, number of injections, and injection-site discomfort, ultimately supporting treatment adherence [3–5].”
Metadata
- Authors
- Umpierrez, G. E., Holt, E. H., Einhorn, D., & McGill, J. B.
- Corresponding author
- Umpierrez, Guillermo E.
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 26
- Issue
- Suppl 3
- Pages
- 1-11
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3019111156
- Cited by
- 44
- References
- 68
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 32 · 2020: 4
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK111024)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- insulin therapy, type 1 diabetes, type 2 diabetes, glycemic control, insulin resistance, obesity, continuous insulin infusion, insulin formulations
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.